<DOC>
	<DOCNO>NCT01709071</DOCNO>
	<brief_summary>A new inactivated polio vaccine base attenuated poliovirus strain develop transfer technology manufacturer low- middle-income country . This vaccine produce different dosage different formulation . In healthy adult safety high dose comparable exist inactivated polio vaccine . The purpose trial determine safety different dosage formulation vaccine infant . The second goal study analyse immune response three dose infant .</brief_summary>
	<brief_title>Safety Immunogenicity New Inactivated Poliovirus Vaccine Infants</brief_title>
	<detailed_description>The goal study assess safety immunogenicity Sabin-IPV adjuvanted Sabin-IPV produce production process set technology transfer National Institute Public Health Environment ( RIVM , formerly Netherlands Vaccine Institute ( NVI ) . - The primary objective evaluate safety ( local systemic reaction ) intramuscular injection Sabin-IPV adjuvanted Sabin-IPV healthy infant . - The secondary objective evaluate immunogenicity three dose Sabin-IPV adjuvanted Sabin-IPV infant .</detailed_description>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>Age 8 week ( 5663 day ) time first vaccination Infants good general health , eligible vaccinate accord Polish national vaccination program . The health criterion apply use wellbaby clinic child receives vaccination , e.g . also child small increase temperature ( &lt; 38.5Â° C ) common cold ( runny nose etc ) see child normal health . The parent ( ) /legally representative ( ) willing able allow child participate trial accord described procedure Presence sign informed consent parent ( ) /legally representative ( ) give write informed consent receive oral write information ( signature one parent case singleparent family ) . Any IPV OPV dose Known suspect allergy vaccine component History unusual severe reaction previous vaccination administration plasma ( include immunoglobulin ) blood product prior study Any vaccination le 14 day vaccination IMP History neurological disorder include epilepsy febrile seizures Any infectious disease time screen and/or inclusion might interfere result study Present evidence serious disease ( ) demand immunosuppressive medical treatment , like cytostatics prednisolone , might interfere result study Any known suspect primary secondary immunodeficiency Communication problem interfere study realization accord judgment investigator Bleeding disorder use anticoagulant Premature birth ( &lt; 37 week ) Participation another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>56 Days</minimum_age>
	<maximum_age>63 Days</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Vaccination</keyword>
	<keyword>Inactivated poliomyelitis vaccine</keyword>
	<keyword>poliomyelitis</keyword>
	<keyword>Sabin strain</keyword>
</DOC>